NCT05285384 - Immunogenicity and Safety of a Booster Dose of the SpikoGen Vaccine in Kidney Transplant Recipients After Two Doses of Sinopharm Vaccine | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 4, 2022

Primary Completion Date

March 30, 2022

Study Completion Date

March 30, 2022

Conditions

COVID-19

Interventions

BIOLOGICAL

SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant

SARS-CoV-2 recombinant spike protein (25 μg) with Advax-SM adjuvant (15 mg); a single intramuscular injection into the deltoid muscle of the non-dominant arm

Trial Locations (1)

Unknown

Shaheed Labbafinezhad Hospital, Tehran